1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Fever – Pipeline Review, H1 2013

Fever – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 41 pages

Fever – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Fever - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Fever, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fever. Fever - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Fever.
- A review of the Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Fever pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Fever.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Fever pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Fever - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Fever Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Fever 7
Fever Therapeutics under Development by Companies 9
Fever Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Fever Therapeutics - Products under Development by Companies 14
Fever Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Fever Therapeutics Development 16
Novartis AG 16
Ahn-Gook Pharmaceutical Co., Ltd. 17
PLx Pharma Inc. 18
Fever - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
canakinumab - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
aspirin - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
daptomycin - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
AG NDP-803 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
Fever Therapeutics - Drug Profile Updates 31
Fever Therapeutics - Dormant Products 34
Fever - Product Development Milestones 35
Featured News and Press Releases 35
May 22, 2012: PLx Pharma Files New Drug Application For PL2200 Aspirin With FDA 35
Feb 06, 2012: Cadence Announces Voluntary Recall Of One Lot Of OFIRMEV Injection 35
Jul 26, 2011: Ceridia Completes Successful Human Clinical Trial 36
Jun 07, 2011: Cadence Pharmaceuticals Announces Addition Of OFIRMEV Injection To US Military's Joint Deployment Formulary 36
May 16, 2011: Caldolor Clinical Study In Hospitalized Burn Patients Published In Journal Of Burn Care and Research 37
Nov 02, 2010: Cadence Receives FDA Approval For OFIRMEV For Management Of Pain And Fever 37
May 14, 2010: Cadence Pharmaceuticals Announces OFIRMEV NDA Action Date Of November 4, 2010 38
May 05, 2010: Cadence Resubmits New Drug Application For OFIRMEV 39
Apr 19, 2010: Cadence Plans To Resubmit NDA For OFIRMEV 39
Nov 13, 2009: Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review For Intravenous Acetaminophen By Three Months 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 41
Disclaimer 41



List of Tables

Number of Products Under Development for Fever, H1 2013 7
Products under Development for Fever - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Late Stage Development, H1 2013 11
Comparative Analysis by Mid Clinical Stage Development, H1 2013 12
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 13
Products under Development by Companies, H1 2013 14
Products under Investigation by Universities/Institutes, H1 2013 15
Novartis AG, H1 2013 16
Ahn-Gook Pharmaceutical Co., Ltd., H1 2013 17
PLx Pharma Inc., H1 2013 18
Assessment by Monotherapy Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
Fever Therapeutics - Drug Profile Updates 31
Fever Therapeutics - Dormant Products 34



List of Figures

Number of Products under Development for Fever, H1 2013 7
Products under Development for Fever - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Late Stage Products, H1 2013 11
Mid Clinical Stage Products, H1 2013 12
Pre-Clinical Stage Products, H1 2013 13
Assessment by Monotherapy Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.